{"id":4780,"date":"2020-06-29T00:00:00","date_gmt":"2022-10-14T16:14:50","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/"},"modified":"2023-05-02T08:45:19","modified_gmt":"2023-05-02T12:45:19","slug":"the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma","status":"publish","type":"eb_course","link":"https:\/\/www.mdbriefcase.com\/fr\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/","title":{"rendered":"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma"},"content":{"rendered":"<p>Australia has one of the\u202fhighest rates of\u202fmelanoma\u202fin the world and as a result, it is often referred to as &#8216;Australia&#8217;s national cancer&#8217;. Skin GPs\u202fand Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new\u202fera of adjuvant immunotherapies for completely resected Stage III\/IV melanoma, sentinel lymph node biopsy (SLNB) plays an important role in\u202fdetermining whether patients are eligible for therapy.\n<\/p>\n<p>This 1-hour RACGP accredited activity aims to equip\u202fSkin GPs and Dermatologists with the information they need to\u202fassist oncologists in\u202fensuring that eligible patients with\u202fcompletely resected Stage III\/IV melanoma\u202fhave access to adjuvant immunotherapy and are supported\u202fthroughout their treatment.\n<\/p>\n<p>It features two cases studies and expert video interviews from the multidisciplinary faculty.\n<\/p>\n<hr>\n<p>This program is supported by an independent educational grant\u202fprovided from Bristol Myers Squibb. <\/p>","protected":false},"featured_media":441169,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-4780","eb_course","type-eb_course","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"Australia has one of the\u202fhighest rates of\u202fmelanoma\u202fin the world and as a result, it is often referred to as &#8216;Australia&#8217;s national cancer&#8217;. Skin GPs\u202fand Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new\u202fera of adjuvant immunotherapies for completely resected Stage III\/IV melanoma, sentinel lymph node [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T12:45:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/\",\"name\":\"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg\",\"datePublished\":\"2022-10-14T16:14:50+00:00\",\"dateModified\":\"2023-05-02T12:45:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#primaryimage\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg\",\"width\":600,\"height\":338},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mdbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\/\/www.mdbriefcase.com\/courses\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mdbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/","og_locale":"fr_CA","og_type":"article","og_title":"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma - MDBriefCase","og_description":"Australia has one of the\u202fhighest rates of\u202fmelanoma\u202fin the world and as a result, it is often referred to as &#8216;Australia&#8217;s national cancer&#8217;. Skin GPs\u202fand Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new\u202fera of adjuvant immunotherapies for completely resected Stage III\/IV melanoma, sentinel lymph node [&hellip;]","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/","og_site_name":"MDBriefCase","article_modified_time":"2023-05-02T12:45:19+00:00","og_image":[{"width":600,"height":338,"url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/","url":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/","name":"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg","datePublished":"2022-10-14T16:14:50+00:00","dateModified":"2023-05-02T12:45:19+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#primaryimage","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/06\/GettyImages-1097423340_LP-19.jpg","width":600,"height":338},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/the-new-era-of-adjuvant-immunotherapy-for-patients-with-completely-resected-stage-iii-iv-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"The new era of adjuvant immunotherapy for patients with completely resected stage III\/IV melanoma"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/4780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=4780"}],"version-history":[{"count":0,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/4780\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media\/441169"}],"wp:attachment":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=4780"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=4780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}